Harrow (HROW) Cash from Investing Activities (2012 - 2026)

Harrow's (HROW) quarterly Cash from Investing Activities came in at -$18.2 million in Q1 2026, down 8486.32% year-on-year from $217055.9 in Q1 2025, and down 284.84% quarter-over-quarter from -$4.7 million in Q4 2025.

Harrow (HROW) Cash from Investing Activities (2012 - 2026) Analysis & Trends

Harrow's Cash from Investing Activities history runs 15 years deep, the most recent figure standing at -$18.2 million for Q1 2026.

  • On a quarterly basis, Cash from Investing Activities fell 8486.32% year-over-year to -$18.2 million in Q1 2026; TTM through Mar 2026 was -$23.5 million, a 29.5% increase from a year earlier, with the FY2025 full-year figure at -$5.5 million, up 83.54% from the prior year.
  • Cash from Investing Activities eased to -$18.2 million in Q1 2026 per HROW's latest filing, from -$4.7 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $5.1 million in Q2 2024 and bottomed at -$131.0 million in Q1 2023.
  • The 5-year median for Cash from Investing Activities is -$410000.0 (2022), against an average of -$12.4 million.
  • Across the five-year window, Cash from Investing Activities sank 31843.9% in 2023 and soared 508.57% in 2024, its largest moves.
  • Year by year, Cash from Investing Activities stood at -$5000.0 in 2022, then tumbled by 3960.0% to -$203000.0 in 2023, then slumped by 18402.46% to -$37.6 million in 2024, then jumped by 87.41% to -$4.7 million in 2025, then sank by 284.84% to -$18.2 million in 2026.
  • Per Business Quant, the three latest HROW Cash from Investing Activities figures stand at -$18.2 million (Q1 2026), -$4.7 million (Q4 2025), and -$225000.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Haleon 89.28 Bn 87.42 Bn - -
2 Teva Pharmaceutical Industries 35.97 Bn 32.23 Bn 1.97 Bn 229.00 Mn
3 Zoetis 32.42 Bn 30.48 Bn 1.62 Bn -87.00 Mn
4 Takeda Pharmaceutical 27.48 Bn 23.42 Bn 4.39 Bn -369.95 Mn
5 United Therapeutics 22.89 Bn 20.73 Bn 648.10 Mn 743.70 Mn
6 RedHill Biopharma 22.11 Bn 22.11 Bn - -
7 Viatris 20.44 Bn 18.64 Bn 1.16 Bn 277.40 Mn
8 Neurocrine Biosciences 17.76 Bn 16.44 Bn 800.70 Mn -506.20 Mn
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn -60.00 Mn
10 Harrow 1.41 Bn 1.32 Bn 27.05 Mn -18.20 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -18.20 Mn
Mar 31, 2026 -18.20 Mn
Dec 31, 2025 -4.73 Mn
Dec 31, 2025 -4.73 Mn
Sep 30, 2025 -225,000.00
Sep 30, 2025 -225,000.00
Jun 30, 2025 -293,000.00
Jun 30, 2025 -293,000.00
Mar 31, 2025 -212,000.00
Mar 31, 2025 -212,000.00
Dec 31, 2024 -37.56 Mn
Dec 31, 2024 -37.56 Mn
Sep 30, 2024 -597,000.00
Sep 30, 2024 -597,000.00
Jun 30, 2024 5.10 Mn
Jun 30, 2024 5.10 Mn
Mar 31, 2024 -110,000.00
Mar 31, 2024 -110,000.00
Dec 31, 2023 -203,000.00
Dec 31, 2023 -203,000.00